S M Keating1, X Deng1, F Fernandes2, E Cunha-Neto3, A L Ribeiro4, B Adesina5, A I Beyer5, P Contestable6, B Custer1, M P Busch7, E C Sabino8. 1. Blood Systems Research Institute, San Francisco, CA, United States; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States. 2. Heart Institute (InCor) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 3. Hospital das Clínicas and Faculdade de Medicina, Universidade Federal de Minas Gerais, Minas Gerais, Brazil; Heart Institute (InCor) da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; Division of Clinical Immunology and Allergy, University of São Paulo School of Medicine, São Paulo, SP 06504-000, Brazil. 4. Hospital das Clínicas and Faculdade de Medicina, Universidade Federal de Minas Gerais, Minas Gerais, Brazil. 5. Blood Systems Research Institute, San Francisco, CA, United States. 6. Ortho Clinical Diagnostics, Rochester, NY, United States. 7. Blood Systems Research Institute, San Francisco, CA, United States; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States. Electronic address: mbusch@bloodsystems.org. 8. Department of Infectious Disease and Institute of Tropical Medicine, University of São Paulo, São Paulo, Brazil.
Abstract
BACKGROUND: Chagas disease has a long clinically silent period following Trypanosoma cruzi infection and before development of overt clinical pathology; detectable biomarkers of infection and pathogenesis are urgently needed. We tested 22 biomarkers known to be associated with cardiomyopathy to evaluate if a biomarker signature could successfully classify T. cruzi seropositive subjects into clinical Chagas disease stage groups. METHODS: This cross-sectional retrospective case-control study enrolled T. cruzi seropositive blood donors (BD) who were further characterized as having chronic Chagas cardiomyopathy (CC-BD) or not (nonCC-BD) and seronegative (SN) control donors; we also included clinically diagnosed Chagas cardiomyopathy patients (CC-P). All subjects underwent a health history questionnaire, medical examination, electro- and echocardiograms (ECG and Echo) and phlebotomy. Biomarkers were measured on blinded samples by luminex bead array and Ortho VITROS. RESULTS: A clear biomarker pattern was observed only in more severe cardiac disease; this pattern included significantly elevated levels of inflammatory cytokines IFN-γ, IL-6, IL-10 and TNF-α and soluble cardiovascular disease biomarkers CK-MB, troponin, myoglobin, VCAM and NTproBNP while there were lower levels of MPO, PAI-1, and MCP-1. The markers determined to be the most predictive of disease by ROC curve analysis were NTproBNP and T. cruzi PCR status. CONCLUSIONS: Although many biomarkers demonstrated increased or decreased concentrations among the clinical forms of Chagas disease, NTproBNP and T. cruzi PCR were the only tests that would independently be of clinical value for disease staging, in concert with ECG, Echo and clinical assessments.
BACKGROUND:Chagas disease has a long clinically silent period following Trypanosoma cruzi infection and before development of overt clinical pathology; detectable biomarkers of infection and pathogenesis are urgently needed. We tested 22 biomarkers known to be associated with cardiomyopathy to evaluate if a biomarker signature could successfully classify T. cruzi seropositive subjects into clinical Chagas disease stage groups. METHODS: This cross-sectional retrospective case-control study enrolled T. cruzi seropositive blood donors (BD) who were further characterized as having chronic Chagas cardiomyopathy (CC-BD) or not (nonCC-BD) and seronegative (SN) control donors; we also included clinically diagnosed Chagas cardiomyopathypatients (CC-P). All subjects underwent a health history questionnaire, medical examination, electro- and echocardiograms (ECG and Echo) and phlebotomy. Biomarkers were measured on blinded samples by luminex bead array and Ortho VITROS. RESULTS: A clear biomarker pattern was observed only in more severe cardiac disease; this pattern included significantly elevated levels of inflammatory cytokines IFN-γ, IL-6, IL-10 and TNF-α and soluble cardiovascular disease biomarkers CK-MB, troponin, myoglobin, VCAM and NTproBNP while there were lower levels of MPO, PAI-1, and MCP-1. The markers determined to be the most predictive of disease by ROC curve analysis were NTproBNP and T. cruzi PCR status. CONCLUSIONS: Although many biomarkers demonstrated increased or decreased concentrations among the clinical forms of Chagas disease, NTproBNP and T. cruzi PCR were the only tests that would independently be of clinical value for disease staging, in concert with ECG, Echo and clinical assessments.
Authors: L La Vecchia; G Mezzena; L Zanolla; M Paccanaro; L Varotto; C Bonanno; R Ometto Journal: J Heart Lung Transplant Date: 2000-07 Impact factor: 10.247
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Amilcar O Mocelin; Victor S Issa; Fernando Bacal; Guilherme V Guimarães; Edecio Cunha; Edimar A Bocchi Journal: Eur J Heart Fail Date: 2005-08 Impact factor: 15.534
Authors: Terry P Combs; Shankar Mukherjee; Cecilia J G de Almeida; Linda A Jelicks; William Schubert; Ying Lin; David S Jayabalan; Dazhi Zhao; Vicki L Braunstein; Shira Landskroner-Eiger; Aisha Cordero; Stephen M Factor; Louis M Weiss; Michael P Lisanti; Herbert B Tanowitz; Philipp E Scherer Journal: J Biol Chem Date: 2005-04-18 Impact factor: 5.157
Authors: Simone G Fonseca; Hélène Moins-Teisserenc; Emmanuel Clave; Bárbara Ianni; Vera Lopes Nunes; Charles Mady; Leo K Iwai; Alessandro Sette; John Sidney; Maria Lúcia C Marin; Anna Carla Goldberg; Luiza Guilherme; Dominique Charron; Antoine Toubert; Jorge Kalil; Edecio Cunha-Neto Journal: Microbes Infect Date: 2005-03-21 Impact factor: 2.700
Authors: L C Abel; L V Rizzo; B Ianni; F Albuquerque; F Bacal; D Carrara; E A Bocchi; H C Teixeira; C Mady; J Kalil; E Cunha-Neto Journal: J Autoimmun Date: 2001-08 Impact factor: 7.094
Authors: Antonio Luiz P Ribeiro; Mauro M Teixeira; Adelina M Reis; Andre Talvani; Amanda A Perez; Márcio Vinicius L Barros; Manoel Otávio C Rocha Journal: Int J Cardiol Date: 2005-07-14 Impact factor: 4.164
Authors: Ana Fernández-Villegas; Elena Pérez-Antón; Inmaculada Gómez; Adriana Egui; M Carmen Thomas; Bartolomé Carrilero; Ángel Del Pozo; Maialen Ceballos; Eduardo Andrés-León; Miguel Ángel López-Ruz; Eusebio Gainza; Enrique Oquiñena; Manuel Segovia; Manuel Carlos López Journal: Antimicrob Agents Chemother Date: 2019-09-23 Impact factor: 5.191
Authors: Jefferson Luis Vieira; Fábio Rocha Fernandes Távora; Maria Gyslane Vasconcelos Sobral; Glauber Gean Vasconcelos; Germana Porto Linhares Almeida; Juliana Rolim Fernandes; Laura Leite da Escóssia Marinho; Daniel Francisco de Mendonça Trompieri; João David De Souza Neto; Juan Alberto Cosquillo Mejia Journal: Curr Cardiol Rep Date: 2019-02-12 Impact factor: 3.955
Authors: Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman Journal: Annu Rev Pathol Date: 2018-10-24 Impact factor: 23.472
Authors: Antonia Pino-Marín; Germán José Medina-Rincón; Sebastian Gallo-Bernal; Alejandro Duran-Crane; Álvaro Ignacio Arango Duque; María Juliana Rodríguez; Ramón Medina-Mur; Frida T Manrique; Julian F Forero; Hector M Medina Journal: Pathogens Date: 2021-04-22